Correspondence 0001193125-24-248124 from Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc.
Date: Oct. 31, 2024 · CIK: 0000882361 · Accession: 0001193125-24-248124
AI Filing Summary & Sentiment
File numbers found in text: 333-281201
Letter
Division of Corporation Finance Office of Life Sciences Attention: Jimmy McNamara and Joe McCann Re: Aptose Biosciences Inc. Registration Statement on Form S-1 Filed August 2, 2024 File No. 333-281201
Dear Sirs and Mesdames:
On behalf of our client, Aptose Biosciences Inc. (the “Company”), and pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder, we transmit for your review the Company’s response to the Staff’s letter of comment, dated August 2, 2024 (the “Comment Letter”), in respect of the above noted filing. The Company’s response below is keyed to the heading and comment number contained in the Comment Letter.
Registration Statement on Form S-1
Cover Page
1. Please revise your cover page to disclose the date your best efforts offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance.
The requested disclosure has been provided on the cover page of the prospectus.
* * *
U.S. Securities and Exchange Commission
October 30, 2024
Page
Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at miller.dan@dorsey.com or fax me at (604) 687-8504.
Yours truly,
/s/ Daniel M. Miller
cc: William G. Rice
Fletcher Payne
Aptose Biosciences Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP DANIEL M. MILLER Partner (604) 630-5199 FAX (604) 687-8504 miller.dan@dorsey.com October 30, 2024 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Jimmy McNamara and Joe McCann Re: Aptose Biosciences Inc. Registration Statement on Form S-1 Filed August 2, 2024 File No. 333-281201 Dear Sirs and Mesdames: On behalf of our client, Aptose Biosciences Inc. (the “Company”), and pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder, we transmit for your review the Company’s response to the Staff’s letter of comment, dated August 2, 2024 (the “Comment Letter”), in respect of the above noted filing. The Company’s response below is keyed to the heading and comment number contained in the Comment Letter. Registration Statement on Form S-1 Cover Page 1. Please revise your cover page to disclose the date your best efforts offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance. The requested disclosure has been provided on the cover page of the prospectus. * * * U.S. Securities and Exchange Commission October 30, 2024 Page 2 Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at miller.dan@dorsey.com or fax me at (604) 687-8504. Yours truly, /s/ Daniel M. Miller cc: William G. Rice Fletcher Payne Aptose Biosciences Inc.